THE PROBLEM
Blindness is the most feared human disability. Corneal disease is one of the leading causes of blindness. However, only 185,00 corneas are transplanted in 116 countries while 12.7 million people are actively awaiting for sight-restoring corneal transplantation.
MARKET FIGURES
185K
Corneas Transplants per Year
12.7M
Actively Awaiting for Corneal Donor Graft
8K
Transplants Doomed to Fail Each Year
>10M
Potential Patients per Year
STATE OF THE ART
For over two centuries, ophthalmologists have sought a reliable artificial cornea—an inert window to restore vision.
Yet, despite pioneering efforts and devices such as the Boston KPro, AlphaCor, and Osteo-Odonto KPro, current implants face major barriers:
-
Direct exposure between eye and environment
-
Severe complications: leakage, infection, extrusion, inflammation, glaucoma
-
Up to 70% complication rate
-
Up to 50% of patients remain legally blind within one year
INTRA-KER SOLUTION
​
Our hybrid intracorneal device is
EXTRAOCULAR for safe implantation
STABLE allowing storage > 12 months
TRANSPARENT for light transmission
ACELLULAR obviating the risk of immune rejection
BIOLOGIC for stable bio-integration
INDEPENDENT of endothelial function
​
This next-generation technology has the potential to redefine eye care and open new commercial opportunities in a rapidly growing ophthalmology market.
​